National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 5819 [2013-01621]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 18 / Monday, January 28, 2013 / Notices
tkelley on DSK3SPTVN1PROD with
meningococcal disease caused by
groups A, C, W–135 and Y Neisseria
meningitidis. Group B capsular PS is
similar to the PS structure expressed in
certain human tissues, thus making it a
poor immunogen. Furthermore, if used
as a vaccine, the possibility exists of it
inducing an autoimmune response.
Thus, a need remains to develop
additional meningococcal vaccines,
particularly for group B and group X
meningococcal serogroups.
This application claims immunogenic
conjugates including at least one
polysaccharide conjugated to a group B
factor H binding protein (fHbp). Also
claimed are immunogenic conjugates
including at least one polysaccharide
conjugated to a Neisserial surface
protein A (NspA). Additionally,
improved methods for preparing
conjugates are claimed.
Potential Commercial Applications:
• Multivalent meningitis vaccine
• Research tool
Competitive Advantages:
• Higher vaccine yield
• More efficient conjugation method
• Lower cost vaccines
Development Stage:
• Pre-clinical
• In vitro data available
• In vivo data available (animal)
Inventors: Che-Hung Robert Lee
(FDA/CBER), Vavlerian Pinto (EM),
Elizabeth Moran (EM), Robert Burden
(EM)
Intellectual Property: HHS Reference
No. E–082–2012/0—U.S. Application
No. 61/651,382 filed 24 May 2012.
Related Technologies:
• HHS Reference No. E–301–2003/
0—U.S. Application No. 13/243,480
filed 06 Aug 2004, claiming priority to
06 Aug 2003
• HHS Reference No. E–085–2005/
0—U.S. Patent 8,173,135 issued 08 May
2012; U.S. Application No. 13/440,856
filed 05 Apr 2012, claiming priority to
17 Mar 2006
Licensing Contact: Peter A. Soukas;
301–435–4646; ps193c@nih.gov
Collaborative Research Opportunity:
The FDA/CBER is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize Multivalent
Meningiococcal Conjugates and
Methods for Preparing Conjugates. For
collaboration opportunities, please
contact Che-Hung Robert Lee at
robert.lee@fda.hhs.gov or 301–451–
5934.
Enhanced Cancer Therapy Using
Photoimmunotherapy (PIT) in
Combination With Anti-Cancer Agents
Description of Technology: The
invention is in the field of
VerDate Mar<15>2010
17:13 Jan 25, 2013
Jkt 229001
Photoimmunotherapy (PIT). More
specifically, the invention relates to
antibody-fluorophore conjugates where
the antibody is specific for cancer cells
and the fluorophore is IR700 dye.
Binding of such conjugates to targeted
cancer cells followed by irradiation with
near infrared light (NIR) was shown to
kill cancer cells in a highly specific
manner. Furthermore, the invention
discloses that the therapeutic effect of
the PIT conjugate is significantly
enhanced by the administration of one
or more anti-cancer agents following the
irradiation step. This is achieved by the
markedly rapid accumulation of the
therapeutic agent in the PIT-treated
tissue. Also provided in the invention
are wearable devices that incorporate
NIR light emitting diodes (LEDs) and
can be used to activate the PIT
conjugates.
Potential Commercial Applications:
Anti-cancer therapy.
Competitive Advantages:
• Highly specific to cancer cells
• Do not affect surrounding normal
cells
• Negligible toxicity
• Enhancement of therapeutic effects
when administered in combination with
one or more other therapeutic agents
• Possible to follow the cell killing
process in real time, using fluorescence
lifetime imaging
Development Stage: In vivo data
available (animal).
Inventors: Hisataka Kobayashi and
Peter L. Choyke (NCI).
Publications:
1. Mitsunaga M, et al. Immediate in
vivo target-specific cancer cell death
after near infrared
photoimmunotherapy. BMC Cancer
2012 Aug 8;12: 345. [PMID 22873679]
2. Mitsunaga M, et al. Near-infrared
theranostic photoimmunotherapy (PIT):
Repeated exposure of light enhances the
effect of immunoconjugate. Bioconjug
Chem. 2012 Mar 21;23(3):604–9. [PMID
22369484]
3. Mitsunaga M, et al. Cancer cellselective in vivo near infrared
photoimmunotherapy targeting specific
membrane molecules. Nat Med. 2011
Nov6;17(12):1685–91. [PMID 22057348]
Intellectual Property:
• HHS Reference No. E–205–2010/
2—PCT Application No. PCT/US2012/
044421 filed 27 Jun 2012
• HHS Reference No. E–250–2010/
1—U.S. Application No. 13/180,111
filed 11 Jul 2011
• HHS Reference No. E–205–2010/
0—U.S. Provisional Application No. 61/
636,079 filed 09 Jul 2010
Licensing Contact: Uri Reichman,
Ph.D., MBA; 301–435–4616;
reichmau@mail.nih.gov.
PO 00000
Frm 00049
Fmt 4703
Sfmt 9990
5819
Dated: January 18, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–01620 Filed 1–25–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity Applications.
Date: February 15, 2013.
Time: 10:00 p.m. to 11:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: January 18, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–01621 Filed 1–25–13; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\28JAN1.SGM
28JAN1
]]>Agencies
[Federal Register Volume 78, Number 18 (Monday, January 28, 2013)]
[Notices]
[Page 5819]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01621]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Time-Sensitive Obesity
Applications.
Date: February 15, 2013.
Time: 10:00 p.m. to 11:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: Michele L. Barnard, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301)
594-8898, barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: January 18, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-01621 Filed 1-25-13; 8:45 am]
BILLING CODE 4140-01-P
